GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), belong to the broader class of therapeutic peptides, which are short chains of amino acids that exert targeted physiologic effects by binding specific receptors. Insulin, one of the earliest and most consequential peptides in clinical medicine, established the foundational proof of concept that endogenous hormone analogs could be synthesized, stabilized, and delivered therapeutically. GLP-1 agents work through this same mechanistic logic, mimicking incretin hormones to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and engage central satiety pathways. Their documented efficacy in glycemic control and weight reduction has driven substantial clinical adoption and parallel interest in the broader peptide pharmacology space.
The growing mainstream visibility of GLP-1 therapies has accelerated consumer and patient interest in a wider category of research and compounded peptides that are not FDA-approved for clinical use, including compounds like BPC-157, TB-500, and various growth hormone secretagogues. These substances are being obtained through gray-market channels and used without physician oversight for purposes ranging from tissue repair to body composition optimization. Unlike regulated GLP-1 therapies, these peptides lack robust human clinical trial data, standardized manufacturing oversight, or established safety profiles. The distinction matters for prescribers because patients presenting for GLP-1 consultations may already be using or asking about these other compounds, creating a clinical responsibility to assess for polypharmacy risk, adulteration exposure, and misaligned expectations about what peptide therapy can and cannot deliver in a regulated, evidence-based context.
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What exactly is a GLP-1 medication?
GLP-1 medications are a class of peptide-based drugs that mimic a naturally occurring hormone in your body called glucagon-like peptide-1. This hormone helps regulate blood sugar, slow digestion, and reduce appetite. Medications like Ozempic, Wegovy, Mounjaro, and Zepbound all work through this peptide pathway.
Are GLP-1 drugs like Ozempic and Wegovy the same thing?
Ozempic and Wegovy both contain the same active ingredient, semaglutide, but they are approved for different purposes and come in different dosing ranges. Ozempic is approved for type 2 diabetes management, while Wegovy is approved specifically for chronic weight management. Your doctor will determine which is appropriate based on your medical history and treatment goals.
Is insulin also a peptide like GLP-1 medications?
Yes, insulin is a peptide hormone, meaning it is made up of a chain of amino acids, just like GLP-1 receptor agonists. Both insulin and GLP-1 medications interact with specific receptors in the body to regulate blood sugar. This shared structural category is part of why peptide-based therapies have become so central to metabolic medicine.
What is the difference between semaglutide and tirzepatide?
Semaglutide, found in Ozempic and Wegovy, activates only the GLP-1 receptor. Tirzepatide, found in Mounjaro and Zepbound, activates both the GLP-1 and GIP receptors, making it a dual-action medication. Clinical trials have shown tirzepatide produces greater average weight loss than semaglutide for many patients.
Are GLP-1 medications safe for long-term use?
Long-term safety data for GLP-1 medications continues to grow, and large clinical trials have demonstrated cardiovascular benefits alongside weight and blood sugar improvements. Like any medication, they carry risks that should be reviewed with your physician, including gastrointestinal side effects and rare concerns such as pancreatitis. Regular monitoring and open communication with your doctor are essential during any extended course of treatment.
Can GLP-1 medications be used by people who do not have diabetes?
Yes, certain GLP-1 medications have received FDA approval for chronic weight management in adults without diabetes who meet specific criteria, such as a BMI of 30 or higher, or 27 or higher with a weight-related health condition. Wegovy and Zepbound are both approved for this indication. A physician evaluation is required to determine whether you qualify and which medication is appropriate for you.
What are the most common side effects of GLP-1 therapy?
The most frequently reported side effects are gastrointestinal in nature, including nausea, vomiting, diarrhea, and constipation, particularly when starting the medication or increasing the dose. These effects often improve over time as the body adjusts to the drug. Gradual dose escalation, dietary modifications, and close follow-up with your physician can help manage these symptoms effectively.
Are compounded versions of semaglutide or tirzepatide safe to use?
Compounded versions of these medications are not FDA-approved and have not undergone the same rigorous manufacturing and safety testing as brand-name products. The FDA has issued warnings about quality and dosing concerns with compounded GLP-1 medications from certain pharmacies. Patients are strongly encouraged to use only FDA-approved medications obtained through legitimate, licensed pharmacies under physician supervision.
How do GLP-1 medications actually cause weight loss?
GLP-1 receptor agonists work through several mechanisms, including slowing gastric emptying, signaling fullness to the brain, and reducing appetite-driving signals in the central nervous system. This combination leads most patients to eat less without feeling deprived in the same way that caloric restriction alone tends to produce. The result is a meaningful and sustained reduction in caloric intake that supports weight loss over time.
How long does it take to see results from a GLP-1 medication?
Most patients begin to notice reduced appetite within the first few weeks of starting therapy, though significant weight loss typically becomes apparent over the first three to six months. Blood sugar improvements in people with type 2 diabetes can occur more quickly, sometimes within the first weeks of treatment. Individual responses vary based on dose, lifestyle factors, and overall health, so consistent follow-up with your physician is important to track your progress.
